Cell and Tissue Engineering in Lymph Nodes for Cancer Immunotherapy

Overview

Journal Adv Drug Deliv Rev

Specialty Pharmacology

Date 2020 Aug 5

PMID 32750376

Citations 29

Authors

Alexander J Najibi

David J Mooney

Affiliations

Soon will be listed here.

Abstract

In cancer, lymph nodes (LNs) coordinate tumor antigen presentation necessary for effective antitumor immunity, both at the levels of local cellular interactions and tissue-level organization. In this review, we examine how LNs may be engineered to improve the therapeutic outcomes of cancer immunotherapy. At the cellular scale, targeting the LNs impacts the potency of cancer vaccines, immune checkpoint blockade, and adoptive cell transfer. On a tissue level, macro-scale biomaterials mimicking LN features can function as immune niches for cell reprogramming or delivery in vivo, or be utilized in vitro to enable preclinical testing of drugs and vaccines. We additionally review strategies to induce ectopic lymphoid sites reminiscent of LNs that may improve antitumor T cell priming.

Citing Articles

Tracing Sentinel Lymph Nodes and Inhibiting Lymphatic Metastasis with TiN Nanobipyramids Through Photothermal Therapy.

Xu Y, Bai X, Chen J, Wu X, Yin D, Yuan G Int J Nanomedicine. 2024; 19:13579-13592.

PMID: 39720216 PMC: 11668323. DOI: 10.2147/IJN.S488480.

Engineering immune organoids to regenerate host immune system.

Patel S, Liu W, K R, McCormick C, Fan Y Curr Opin Genet Dev. 2024; 89:102276.

PMID: 39509964 PMC: 11588509. DOI: 10.1016/j.gde.2024.102276.

Therapeutic Immunomodulation of Tumor-Lymphatic Crosstalk via Intratumoral Immunotherapy.

Lucas S, Thomas S Mol Pharm. 2024; 21(12):5929-5943.

PMID: 39478434 PMC: 11615947. DOI: 10.1021/acs.molpharmaceut.4c00692.

Lymphocyte homing and recirculation with tumor tertiary lymphoid structure formation: predictions for successful cancer immunotherapy.

Tian W, Wei W, Qin G, Bao X, Tong X, Zhou M Front Immunol. 2024; 15:1403578.

PMID: 39076974 PMC: 11284035. DOI: 10.3389/fimmu.2024.1403578.

Targeting lymph nodes for enhanced cancer vaccination: From nanotechnology to tissue engineering.

Wang J, Zhang Z, Liang R, Chen W, Li Q, Xu J Mater Today Bio. 2024; 26:101068.

PMID: 38711936 PMC: 11070719. DOI: 10.1016/j.mtbio.2024.101068.

References

Lin H, Wang W, Huang Y, Liao W, Lin T, Lin S . Decellularized Lymph Node Scaffolding as a Carrier for Dendritic Cells to Induce Anti-Tumor Immunity. Pharmaceutics. 2019; 11(11). PMC: 6920996. DOI: 10.3390/pharmaceutics11110553. View

Novak R, Ingram M, Marquez S, Das D, Delahanty A, Herland A . Robotic fluidic coupling and interrogation of multiple vascularized organ chips. Nat Biomed Eng. 2020; 4(4):407-420. PMC: 8057865. DOI: 10.1038/s41551-019-0497-x. View

von Andrian U, Mempel T . Homing and cellular traffic in lymph nodes. Nat Rev Immunol. 2003; 3(11):867-78. DOI: 10.1038/nri1222. View

Yang X, Lian K, Meng T, Liu X, Miao J, Tan Y . Immune Adjuvant Targeting Micelles Allow Efficient Dendritic Cell Migration to Lymph Nodes for Enhanced Cellular Immunity. ACS Appl Mater Interfaces. 2018; 10(39):33532-33544. DOI: 10.1021/acsami.8b10081. View

Varypataki E, Silva A, Barnier-Quer C, Collin N, Ossendorp F, Jiskoot W . Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles. J Control Release. 2016; 226:98-106. DOI: 10.1016/j.jconrel.2016.02.018. View

Wigle J, Oliver G . Prox1 function is required for the development of the murine lymphatic system. Cell. 1999; 98(6):769-78. DOI: 10.1016/s0092-8674(00)81511-1. View

Giese C, Lubitz A, Demmler C, Reuschel J, Bergner K, Marx U . Immunological substance testing on human lymphatic micro-organoids in vitro. J Biotechnol. 2010; 148(1):38-45. DOI: 10.1016/j.jbiotec.2010.03.001. View

Dieu-Nosjean M, Antoine M, Danel C, Heudes D, Wislez M, Poulot V . Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008; 26(27):4410-7. DOI: 10.1200/JCO.2007.15.0284. View

Cuzzone D, Albano N, Aschen S, Ghanta S, Mehrara B . Decellularized Lymph Nodes as Scaffolds for Tissue Engineered Lymph Nodes. Lymphat Res Biol. 2014; 13(3):186-94. PMC: 4575505. DOI: 10.1089/lrb.2013.0054. View

10.

Wang T, Wang D, Yu H, Feng B, Zhou F, Zhang H . A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors. Nat Commun. 2018; 9(1):1532. PMC: 5906566. DOI: 10.1038/s41467-018-03915-4. View

11.

Yagawa Y, Robertson-Tessi M, Zhou S, Anderson A, Mule J, Mailloux A . Systematic Screening of Chemokines to Identify Candidates to Model and Create Ectopic Lymph Node Structures for Cancer Immunotherapy. Sci Rep. 2017; 7(1):15996. PMC: 5700067. DOI: 10.1038/s41598-017-15924-2. View

12.

Stephan S, Taber A, Jileaeva I, Pegues E, Sentman C, Stephan M . Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol. 2014; 33(1):97-101. PMC: 4289408. DOI: 10.1038/nbt.3104. View

13.

Weiden J, Voerman D, Dolen Y, Das R, van Duffelen A, Hammink R . Injectable Biomimetic Hydrogels as Tools for Efficient T Cell Expansion and Delivery. Front Immunol. 2018; 9:2798. PMC: 6279891. DOI: 10.3389/fimmu.2018.02798. View

14.

Hammerich L, Marron T, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S . Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019; 25(5):814-824. DOI: 10.1038/s41591-019-0410-x. View

15.

Fan L, Reilly C, Luo Y, Dorf M, Lo D . Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis. J Immunol. 2001; 164(8):3955-9. DOI: 10.4049/jimmunol.164.8.3955. View

16.

Ventura Ferreira M, Bergmann C, Bodensiek I, Peukert K, Abert J, Kramann R . An engineered multicomponent bone marrow niche for the recapitulation of hematopoiesis at ectopic transplantation sites. J Hematol Oncol. 2016; 9:4. PMC: 4727380. DOI: 10.1186/s13045-016-0234-9. View

17.

Conniot J, Scomparin A, Peres C, Yeini E, Pozzi S, Matos A . Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nat Nanotechnol. 2019; 14(9):891-901. DOI: 10.1038/s41565-019-0512-0. View

18.

Dura B, Dougan S, Barisa M, Hoehl M, Lo C, Ploegh H . Profiling lymphocyte interactions at the single-cell level by microfluidic cell pairing. Nat Commun. 2015; 6:5940. DOI: 10.1038/ncomms6940. View

19.

Sancho D, Mourao-Sa D, Joffre O, Schulz O, Rogers N, Pennington D . Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest. 2008; 118(6):2098-110. PMC: 2391066. DOI: 10.1172/JCI34584. View

20.

Agliari E, Biselli E, De Ninno A, Schiavoni G, Gabriele L, Gerardino A . Cancer-driven dynamics of immune cells in a microfluidic environment. Sci Rep. 2014; 4:6639. PMC: 5377582. DOI: 10.1038/srep06639. View